Download App

Log in to access Online Inquiry
Company Overview More
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn’s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still’s disease, including adult-onset still’s disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
CEO: Neil M.D., Garry A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > AVTX Avalo Therapeutics > Detailed Quotes

AVTX Avalo Therapeutics

0.325+0.005+1.53%
Close 05/20 20:00 ET
0.334+0.0091+2.80%
Post Mkt Price 05/20 17:41 ET
High
0.346
Open
0.346
Turnover
155.26K
Low
0.300
Pre Close
0.320
Volume
482.72K
Market Cap
36.65M
P/E(TTM)
Loss
52wk High
3.700
Shares
112.79M
P/E(Static)
Loss
52wk Low
0.202
Float Cap
12.63M
Bid/Ask %
75.44%
Historical High
7.650
Shs Float
38.86M
Volume Ratio
0.95
Historical Low
0.202
Dividend TTM
--
Div Yield TTM
--
P/B
5.80
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.24%
Amplitude
14.25%
Avg Price
0.321
Lot Size
1
Float Cap
12.63M
Bid/Ask %
75.44%
Historical High
7.650
Shs Float
38.86M
Volume Ratio
0.95
Historical Low
0.202
Dividend TTM
--
P/B
5.80
Dividend LFY
--
Turnover Ratio
1.24%
Amplitude
14.25%
Avg Price
0.321
Lot Size
1
Price Forecast

No Data

News

Comment